Stan Piland is a private investor with over 20 years experience in institutional equity sales and trading. His portfolio is actively managed, and he employs a multidisciplinary strategy incorporating elements of both value and growth styles. His investment horizon can be anywhere from several weeks to several years for core positions. While the portfolio usually has a long bias, market risk is occasionally hedged with ETFs, options and short sales. Mr. Piland holds a degree in Government and an advanced degree in Economics and Finance.
I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
James has degrees in both Economics and Political Science. He is a small business owner with several years of past political experience and 17 years of active investing.
You can get a 48-72 hour advantage on all his work through Value Investor's Edge as well as exclusive research and analysis by J. Mintzmyer.
I am an adjunct faculty member at the R. H. Smith School of Business at the University of Maryland. With the help of my students I focus on fundamental equity research, reviewing over 120 companies a year. This site is used to publish a sampling of the research we produce. The goal is to give the students an opportunity to participate in the production of high quality research similar to what will be demanded from them in industry. The methodology we employ was developed at Johns Hopkins under the direction of Prof. Steve Hanke. This approach is centered around the proprietary concept of Sustainable Free Cash Flow and deviates significantly from many of the popular valuation protocols. Most significantly, it treats the subject company as an on-going system that the stock price tracks. As a result, the process focuses on historical distributions of parameters that in combination, produce various levels of cash flow per share. The stock price is then compared to this output in order to ascertain its probable direction.
I have been managing long/short assets in the financial sector for over ten years. I currently work at a predominate hedge fund and manage a long/short strategy focused on the financial services industry. Previously, I worked at a mutual fund firm for seven years where I managed a long/short financials hedge fund. I also co-managed a diversified equity mutual fund. My prior investment experience includes equity analysis a mutual fund firm based in Boston. I graduated cum laude from Rensselaer Polytechnic Institute with a BS in Physics and a concentration in Astrophysics. I received my MBA with Honors from MIT Sloan School of Management.
TheStreetSweeper recently named Sonya Colberg as Senior Editor. About three years ago, she became senior investigative reporter of TheStreetSweeper, a website devoted to exposing fraud, shenanigans and lousy business practices of public companies. Sonya had worked more than two decades as an editor and reporter for two major newspapers, including the recent Warren Buffett acquisition, Tulsa World. Among others, the Associated Press, Great Plains Journalism Awards, The Gerald Loeb Awards and the Society of Professional Journalists have recognized Sonya’s investigative, feature, health, news and business stories. A fearless investigative reporter, Sonya loves nothing better than calling out the shysters and bumblers who quietly work to separate investors from their hard-earned money.
Copperfield Research is the pseudonym of a research team focusing on publicly traded equities. As of the publication date of our articles, we may have long or short equity positions in the companies covered. We do not discuss unpublished reports, or provide any advanced warning of future reports to others. Due to the danger of retaliation, our reports are written under a pseudonym. Please read our Disclaimer on the front page of every opinion piece before reading any of the material.
I have spent my entire career, 15+ years, in the asset management industry. I have experience spanning multiple economic cycles and multiple assets classes. My career has been marked with diversity, partly by design and partly by luck. Over the course of 15 years, I have done just about every investment related activity from the back office to the front office from analyst to manager. I have worked for small entrepreneurial firms with less than 30 people to large ones with over 1500. I have worked for quantitative firms and fundamental ones. I mostly focus on long only investing but did work for several years on a market neutral fund. My experience with asset classes ranges from equities to corporate bonds and loans to alternatives like PE, VC, real assets and currencies.
For the past 8 years, I have been doing fundamental research on stocks, bonds and loans, as an investment analyst for a mutual fund. My sector focus is Technology and Automotive.
I have an MBA and have earned the Chartered Financial Analyst (CFA) designation.
I am an attorney in Baltimore, Md., representing children with lead poisoning. I have been investing in biotech for over a decade.
I have an A.B. from Vassar College '76, Phi Beta Kappa; J.D. from Duke Law School '79; M.S. from Johns Hopkins University '08.
Chief Investment Officer, Stanford Wealth Management. Retired senior exec of Charles Schwab. 36 years active and reserve military service -- 6 in special operations, 30 in the intelligence community. Geopolitical analyst.
Author -- investment book Bringing Home the Gold.
Editor -- The Investor’s Edge®. In the 16 years from inception through year-end 2015, the Investor’s Edge® Growth & Value Portfolio increased in value from $250,000 to $1,038,453. That same $250,000 invested in the S&P 500 rose to just $422,905. (Past results are no guarantee of future performance; maybe those 16 years were pure luck.)
Featured in Forbes, Barrons, The Wall Street Journal, Financial World, Wall Street Transcript, Global Investing, Welling on Wall Street, etc.
If you have a $500,000 portfolio ($250,000 for solely mutual funds & ETFs) you may contact me for a no-obligation "second opinion." firstname.lastname@example.org.
H. Jack Bouroudjian is the host of the syndicated program “The Jack B. Show” on the Salem Radio Network, a regular commentator on CNBC, author of “Secrets of the Trading Pros” (Wiley, 2007) and a columnist for Townhall Finance. He is also chairman of Bull & Bear Partners, a financial services holding company based in Chicago.
Previously, Mr. Bouroudjian served as senior vice president of equity futures for Nikko Securities, the second-largest securities firm in Japan, and Credit Agricole Futures, a wholly owned subsidiary of Credit Agricole, the 17th-largest bank in the world. He was also president of Commerz Futures, a subsidiary of Commerz Bank, the fourth-largest bank in Germany. He served on the Chicago Mercantile Exchange Board of Directors from 1996-2002, where he acted as chairman or co-chairman of several educational, product and regulatory committees during his term.
Barry Randall is the Chief Investment Officer of Crabtree Asset Management. Barry founded Crabtree in 2008 following a 15-year Wall Street career as an equity analyst and portfolio manager specializing in growth stocks. In 2007, Barry earned a Wall Street Journal Category King award for his co-management of the MTB Small Cap Growth Fund in 2006. He holds a Bachelor of Science in Mathematics from the University of Massachusetts at Amherst and an MBA from the University of Texas, Austin. Crabtree Asset Management is a registered investment adviser based in Saint Paul, Minnesota. Formed in 2008, Crabtree offers traditional advisory services to individuals and families. The firm has a specialization in growth stocks in general and technology stocks in particular. However, Crabtree clients' needs are addressed based solely on their unique situation and investment goals.
I've been in investment management since 1990, currently as the money manager for Worm Capital. I received my law degree from the University of Oregon in 1984, worked as an accountant for the international accounting firm KPMG, then got involved in investing. I've written over 300 columns for The Financial Times, TheStreet.com, Realmoney.com and SeekingAlpha.com.
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
Andrew Left's Citron Research (http://www.citronresearch.com/) (formally known as Stocklemon.com) seeks to expose companies whose management is in some way misleading investors. Left digs into SEC filings, financials, management histories and other data to uncover such situations, and he is usually short the stocks he writes about. Mr. Left has been publishing for 7 years and has created a track record that is unrivaled in short selling. Mr. Left has been cited in Barron's, Wall St Journal, CNBC and other major publications repeatedly for his work. Mr. Left was also an invited speaker at the reknown Master Investor Conference.
Visit: Citron Research (http://www.citronresearch.com/)
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA). Their published work includes freelance and editorial contributions both print and on-line, clinical and medical research, books and tutorials, as well as contributions to on-line social media. Through these and other activities they were able to collaborate and connect amongst themselves to establish this cadre of like-minded biotech/pharma trading and investing aficionados.
The Team includes:
Chief Scientific Analyst - Jason Chew
Chief Research Analyst - Patrick Crutcher
Chief Medical Analyst - Dr. Tro Kalayjian
CEO & Trading Analyst - Tony Pelz
Research Analyst - Dr. Andrew Goodwin
Research Analyst - Dr. Juan Pedro Rodríguez Serrate
Technical Analyst - Joe Gantoss
Research Analyst - Dr. Steven Murphy
Bill Simpson has been trading for a living since the late '90's, focusing on initial public offerings in the aftermarket -- and with great success (up an annualized average of 32% since 2000). His strength is analyzing upcoming offerings with a focus on determining and estimating potential market fair value before it opens for trading. Mr. Simpson's outstanding, indepth IPO reports are an important component of Seeking Alpha's IPO coverage.
Bill Simpson's subscription-based research is available on his site:
Stan Piland is a private investor with over 20 years experience in institutional equity sales and trading. His portfolio is actively managed, and he employs a multidisciplinary strategy incorporating elements of both value and growth styles. His investment horizon can be anywhere from several weeks to several years for core positions. While the portfolio usually has a long bias, market risk is occasionally hedged with ETFs, options and short sales.
Mr. Piland holds a degree in Government and an advanced degree in Economics and Finance.
Shaun Rein is the Founder and Managing Director of the China Market Research Group (CMR), the world's leading strategic market intelligence firm focused on China. He works with Fortune 500 and leading Chinese companies, private equity firms, SMEs, and hedge funds. Clients include Apple, Yum! Brands, Richemont, DuPont, Ecco Shoes, LG Electronics, Samsung, Unitas Capital, CLSA, China Capital Today, Hutchison Whampoa, Lane Crawford, Hard Rock International.
He is the author of the international best-selling book "The End of Cheap China: Economic and Cultural Trends that will Disrupt the World” published by John Wiley & Sons in the US.
Rein is a columnist for Bloomberg BusinessWeek on business in China and teaches executive education classes for the London Business School. He previously was a columnist for CNBC and Forbes. He is often featured in the Wall Street Journal, Fortune, and The Financial Times and frequently appears on CNBC, Bloomberg, BBC, and CNN.
He earned his Master's degree from Harvard University focused on China's economy and received a BA Honours from McGill University. He sits on the Asia Council for St. Paul's School.
Steve Rubens is an international transactions consultant with a background in law and finance. He teaches classes on international transactional law and provides advisory services on investments in Brazil and other emerging markets through Nomad Advisory.